



\$~87

* **IN THE HIGH COURT OF DELHI AT NEW DELHI**

+ **W.P.(C) 6603/2025**

**MASTER ADWAIT HARITAS THROUGH HIS FATHER AND
NATURAL GUARDIAN MR VIVEK SHARMAPetitioner**

Through: Mr. Piyush Sanghi, Advocate along
with Ms. Khushbu Sahu, Mr. Nikhil
Singh, Mr. Raahithya Raj Mishra, Mr.
Ashish Mishra, Ms. Anushka Ojha
and Mr. Akshay Anumandala,
Advocates.

versus

**UNION OF INDIA THROUGH SECRETARY MINISTRY OF
HEALTH AND FAMILY WELFARE & ORS.Respondents**

Through: Mr. Ripudaman Bhardwaj, CGSC
along with Mr. Vedansh Anand, GP
for UOI.
Mr. Tanveer Oberoi, Advocate for
AIIMS.

**CORAM:
HON'BLE MR. JUSTICE SACHIN DATTA**

**ORDER
18.08.2025**

%

1. Learned counsel appearing for the All India Institute of Medical Sciences (AIIMS) has handed over a status report pursuant to the directions contained in the order dated 11.08.2025, wherein, it has been stated as under:-

“3. That the petitioner was examined over video teleconsultation on 21.06.2025 and subsequently an in-person clinical evaluation was carried out in the Child Neurology OPD on 28.06.2025.

4. That thereafter, the petitioner's case was forward to the COE Committee, AIIMS for further consideration. Subsequent thereto, a



meeting of the COE Committee, AIIMS, was held on 18.07.2025 during which meeting it was decided that Rs.50 lakhs financial assistance under the National Policy for Rare Diseases-2021 may be extended to the petitioner. Copy of the Minutes of the Meeting of the COE Committee, AIIMS held on 18.07.2025 are annexed herewith and marked as ANNEXURE R-1.

5. That vide letter dated 13.08.2025, sent to the Hospital Billing Section & Senior Store Officer, AIIMS, request was made to procure as many units of the medicine "RISDIPLAM" as possible within the amount of Rs.50 lakhs. Copy of the letter dated 13.08.2025 is annexed herewith and marked as ANNEXURE R-2.

6. That accordingly, it is submitted that as soon as the medicines are procured by the Hospital Stores department, the treatment of the petitioner shall be commenced in compliance with the directions of this Hon'ble Court."

2. Let the process for procurement of medicines, as referred to in the aforesaid status report be expedited, so that the necessary treatment can be given to the petitioner on priority.
3. Let the necessary process for procuring the medicines be concluded within a period of four weeks from today.
4. It is further directed that in the event of any current or future clinical trials or investigational therapy, which is relevant to the petitioner's affliction, the Drug Controller General of India (DCGI) may consider the petitioner for 'priority inclusion' therein.
5. List on 24.09.2025.

SACHIN DATTA, J

AUGUST 18, 2025/r